http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-115017-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7c3514329baa75dcef8279fdf30ad5a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7c0df625f0081363cbebef5065a77c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b36099b7f492229cb14b854000c235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c8d5e8b454b4bc42025364c73e0de3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_891edaac8a647718ee1a6db0fcf742e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37d7602bda2969b4cb4532981659fff9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50a944871e2f47bd366d3a3e2a64e310 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_953a7e19a1aacc6708d85f4b53296bc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cd22c4a109692809be3ee12c2635efa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd7ad388243233fa4ba55d489fcb84e |
| publicationDate | 2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-115017-A1 |
| titleOfInvention | DERIVATIVES OF N- (3- (7H-PIRROLO [2,3-D] PYRIMIDIN-4-IL) PHENYL) BENZAMIDE |
| abstract | The present one relates to compounds of formula (1) or a pharmaceutically acceptable salt thereof, where the substituents are as defined in the specification; with intermediaries in the preparation of the compounds, with pharmaceutical compositions comprising the compounds and with the use of the compounds in the treatment of diseases. Claim 1: A compound of formula (1), where: R¹, R¹ᵃ, R² and R²ᵃ are independently selected at each occurrence from H and F; R⁶ is H or F; R⁷ is selected from H, F, Cl, -CH₃, -OCH₃, and -OCH₂CH₃; X¹ is a group of the formula (2) or (3), where * X¹ᵃ is selected from * - (CH₂) ₁₋₃-, and * -CH₂C (CH₃) ₂-, where * indicates the point of attachment of the group X¹ᵃ with the phenyl ring in formula (1); * X¹ᵇ is selected from * -O-, * -OCH₂-, and * -CH₂O- where the * indicates the point of attachment of the group X¹ᵇ with the phenyl ring in formula (1); X²ᵃ is selected from the formula (4), (5), (6), (7) and (8), where ** indicates the point of attachment with X¹ᵃ; X²ᵇ is selected from formula (9) and (10), where ** indicates the point of attachment with X¹ᵇ; X⁵ is CH or N; X⁶ is CH or N; R³ is H or -CH₃; R⁴ is H or -CH₂OH; R⁵ is H or -CH₂OH; Z is absent or * - (CH₂) ₂₋₃NH-, where * indicates the point of attachment of Z to the N atom in formula (4); Z¹ is selected from * -O-, * -C (O) -, * - (CH₂) ₁₋₃-, * - (CH₂) ₂O-, and * -CH₂CH (CH₂OH) O-, where * indicates the point binding of Z¹ with X⁵ in formula (6) and formula (9); Z²ᵃ is absent or -NH (CH₂) ₄ - **; Z²ᵇ is - (CH₂) ₃₋₄NH (CH₂) ₂ - **; Z³ is absent or ** - (CH₂) ₄NH-, where Z²ᵃ and Z³ are not absent at the same time; and where ** in each of Z²ᵃ, Z²ᵇ and Z³ indicates the point of attachment with the respective N atoms in formulas (7) and (10); q is 0 or 1; and n and p are independently 0 or 1; and where (i) when Z¹ in formula (6) or in formula (9) is * -O-, then X⁵ and X⁶ are not N, and (ii) when Z¹ in formula (6) or in formula (9) is * - (CH₂) ₂-O- or * -CH₂CH (CH₂OH) O- then X⁶ is not N; or one of its pharmaceutically acceptable salts. |
| priorityDate | 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.